Updated information and services can be found at: 14␣ demethylase [14DM] ), or in various efflux pumps from both the ABC transporter and major facilitator gene families. To determine which of these possible mechanisms was associated with the development of drug resistance in a particular case, mRNA levels have been studied in a series of 17 clinical isolates taken from a single HIV-infected patient over 2 years, during which time the levels of fluconazole resistance of the strain increased over 200-fold. Using Northern blot analysis of steady-state levels of total RNA from these isolates, we observed increased mRNA levels of ERG16 (the 14DM-encoding gene), CDR1 (an ABC transporter), and MDR1 (a major facilitator) in this series. The timing of the increase in mRNA levels of each of these genes correlated with increases in fluconazole resistance of the isolates. Increased mRNA levels were not observed for three other ABC transporters, two other genes in the ergosterol biosynthetic pathway, or the NADPH-cytochrome P-450 oxidoreductase gene that transfers electrons from NADPH to 14DM. Increases in mRNA levels of ERG16 and CDR1 correlated with increased cross-resistance to ketoconazole and itraconazole but not to amphotericin B. A compilation of the genetic alterations identified in this series suggests that resistance develops gradually and is the sum of several different changes, all of which contribute to the final resistant phenotype.
Oral candidiasis is recognized as one of the earliest and most frequent opportunistic infections associated with AIDS (10) . Candidiasis is caused by the opportunistic yeast Candida albicans and related yeasts (25) . Oral candidiasis has been controlled largely by use of the systemic azole drug fluconazole and topical azole and polyene drugs. However, the use and occasional overuse of fluconazole has resulted in the emergence of azole-resistant strains of Candida (34) . One recent estimate suggests that up to 33% of AIDS patients have an oral commensal strain of Candida that is azole resistant (20) .
The azole drugs are fungistatic and work by competitive inhibition of lanosterol 14␣ demethylase (14DM), part of the biosynthetic pathway of ergosterol, a major and necessary membrane sterol (18, 25) . ERG16, the gene coding for 14DM from C. albicans, has been cloned and sequenced (15, 19) , as have two other genes in the ergosterol biosynthetic pathway, those encoding squalene epoxidase (ERG1) (17, 42) and oxidosqualene cyclase (ERG7) (13, 36) , and the gene coding for NADPH-cytochrome P-450 oxidoreductase that transfers electrons from NADPH to 14DM (PDR1) (38) . Biochemical analysis of azole-resistant strains of C. albicans has demonstrated that alterations in the ergosterol biosynthetic pathway are associated with azole resistance (11) .
Recently, evidence has been presented that efflux of the azole drugs from the cells is associated with azole resistance (5, 26, 27, 40, 41) . Sanglard and coworkers (41) have shown increased mRNA levels of the CDR1 and MDR1 genes in azoleresistant clinical isolates of Candida. CDR1 is a member of the ABC transporter family of efflux pumps and MDR1 is a member of the major facilitator family of pumps. Recently, this group has shown that genetic knockouts of these pumps in Candida result in hypersensitivity to antifungal drugs as well as other metabolic inhibitors (40) .
The ABC transporters are a gene family of efflux pumps associated with the movement of small molecules across the plasma membrane (24) . Four families of ABC transporters, MDR, CFTR, YEF, and PDR, have been identified in Saccharomyces cerevisiae based on gene homologies (24) . To date, eight genes for ABC transporters have been identified in Candida. These genes include five CDR genes (CDR1 to CDR5) (3, 38, 39) that are members of the PDR gene family, HST6 from the MDR family (31), YCF1 from the CFTR family (16) , and ELF1 from the YEF family (43) .
The major facilitators are a related family of genes coding for efflux pumps (23) . Family members include many transport molecules of prokaryotic cells, including the tetracycline transporter. The MDR1 gene is the only major facilitator that has been cloned from Candida (2, 7, 9) .
A series of 17 isolates collected during a 2-year period from a single AIDS patient has been studied extensively, because resistance to fluconazole developed gradually in this series and is correlated with the doses that were given to the patient (29, 32, 48) . The isolates represent a single strain of C. albicans (29, 32, 48) , although Ca3 typing indicates that one substrain is replaced by a closely related substrain between isolates 1 and 2 in the series (48) . The phenotype of the resistant isolate is stable for at least 600 generations (48) .
This study continues the characterization of the resistance mechanisms present in this series of isolates. mRNA levels of ERG16, MDR1, and CDR1 as well as other genes that might be involved in resistance were investigated. By using the entire series of isolates, the timing of these changes has been resolved. In addition, MICs of other azoles (ketoconazole and itraconazole) and of amphotericin B have been monitored in this series.
MATERIALS AND METHODS
Strains and growth of cultures. The C. albicans isolates used in this study were obtained from single colonies and include 16 of the series of 17 oral isolates from a single patient. The remaining isolate in the series, isolate 10, was not available for analysis. The control strain was laboratory strain 3153A (ATCC 28367).
Isolates were maintained at 25°C on YEPD agar plates (10 g of yeast extract, 20 g of peptone, 20 g of dextrose, and 15 g of Bacto Agar per liter) and subcultured weekly or were stored at Ϫ70°C in YEPD containing 10% glycerol. Cell cultures were inoculated with a single colony grown on a YEPD agar plate. Culture media components were obtained from Fisher Scientific Co. (Pittsburgh, Pa.). MICs of ketoconazole, itraconazole, and amphotericin B were determined using E-test strips (AB Biodisk North America Inc., Piscataway, N.J.) following the manufacturer's instructions. All E-test results were confirmed by the National Committee for Clinical Laboratory Standards broth macrodilution method (8) .
RNA manipulations and Northern blots. All RNAs were prepared from logarithmically growing cells in the absence of azole drugs. RNA preparation and gel electrophoresis, Northern blotting, PCR amplification, labeling with polynucleotide kinase, and random priming for radioactive probe preparation were performed according to standard published methods (1, 22, 37) .
The 10 probes that were used for Northern blots were prepared in several ways. Three different methods were used to prepare probes, because three different types of DNA were available to the author. Six probes were synthesized by PCR amplification using the oligonucleotide sets. Plasmids containing gene inserts were used for three probes, and a long oligonucleotide (50 nucleotides) was used for the final probe. Table 1 presents the 10 probes, the types of DNA used, the types of radioactive labeling used, the positions within the sequence from which the oligonucleotides were designed, and the GenBank reference numbers of the sequences. The choice of probe labeling was dictated by the type of DNA available. All of the probes were within the coding regions of the genes.
PCR fragments were purified from the oligonucleotide primers by spin column chromatography (28) and labeled by random priming with [␣-32 P]dATP and the large subunit of DNA polymerase I (Klenow fragment). Plasmid probes were prepared by random priming of plasmids containing the gene. The ACT1 probe was synthesized as an oligonucleotide as previously described (46) and labeled with polynucleotide kinase and [␥-32 P]ATP. Unincorporated nucleotides were removed from each probe by spin column chromatography (28) .
For quantitation, autoradiograms were scanned with a Sharp high-resolution color scanner, using the Adobe Photo Shop program, and quantitated by using the Molecular Dynamics ImageQuaNT program. Bands were compared after adjustment for differences in loading, based on the quantitation of actin bands, and for background. Isolates are shown on the x axis in the order in which they were obtained from the patient. The doses that was administered to the patient at the time of each isolate are shown (E) (48) . Doses are given on a linear scale on the y axis to the right. MICs of fluconazole were determined by broth macrodilution (ᮀ) and broth microdilution (s) assays (48) . Only two differences are observed between the two methods. MICs of itraconazole (å), ketoconazole (Ç), and amphotericin B (}) were determined by E-tests and confirmed by National Committee for Clinical Laboratory Standards broth macrodilution assays. MICs are given on a logarithmic scale on the y axis to the left. Genetic changes that were identified are summarized above the graph and are described in detail in the text. Alterations that have been previously described are in lightface text, including the Ca3 restriction fragment length polymorphism (RFLP) (48) as well as the changes in the ERG16 gene and enzyme (44) . Changes in mRNA levels are shown in boldface type and were first identified in this work. 17. The MICs of both drugs are increased by Ͼ1 log between the first and last isolates. The MICs of amphotericin B are unchanged in the series. Increased mRNA levels of ERG16 without gene amplification. Increased expression of the target enzyme is a common phenomenon in eukaryotic drug resistance and has rarely been described previously for Candida. Total RNA was prepared from the 17 isolates grown in the absence of drug. Northern blots of these RNAs were probed with a gene fragment from ERG16 and with an oligonucleotide for actin (ACT1) as a control (Fig. 2) . Although some variability in signal was observed, densitometric analysis of the Northern blot in Fig. 2 indicated that the ERG16 signal did not increase significantly until isolate 13. mRNA levels of ERG16 are increased in isolates 13 to 17 approximately four-to fivefold compared to those in isolates 1 to 12. This increase coincides with a recently identified point mutation in ERG16 and with the loss of allelic variation in the ERG16 genomic region (44) .
RESULTS

Cross
Overexpression of a gene in eukaryotic drug resistance is usually associated with gene amplification. To test for this possibility, Southern blots of genomic DNA from the 17 isolates digested with HincII were hybridized with a gene probe to ERG16 (Fig. 3) . The ERG16 gene is not appreciably amplified in the series. In addition, HincII divides the ERG16 gene into three fragments encoding the 5Ј end of the gene, an internal fragment, and the 3Ј end of the gene. The constant pattern of these fragments in the genomic Southern blots (Fig. 3) suggests that large-scale rearrangements have not occurred in the region surrounding the ERG16 gene.
Increased mRNA levels of MDR1 and CDR1. Sanglard and coworkers have shown that mRNA levels of MDR1 and CDR1 are increased in several fluconazole-resistant isolates of C. albicans (41) . Northern blots of total RNA from the series of 17 isolates were hybridized with an MDR1 gene probe (Fig. 4) and with a CDR1 gene probe (Fig. 5) . mRNA levels of MDR1 are not detectable in isolate 1 and are dramatically increased in isolates 2 and 3 (Fig. 4) . The signal from isolate 2 is at least 12-fold greater than that from isolate 1, and that from isolate 3 is approximately 25-fold greater than the signal from isolate 1. The high levels of mRNA for MDR1 seen in isolate 3 continue for the rest of the series. RNA from isolate 13 was slightly degraded in this particular gel, but the decrease in signal intensity for the ACT1 control was comparable to the decrease in the MDR1 signal. This observation was confirmed by phosphorimager analysis and repeated with other RNA samples. The mRNA for CDR1 is present at constant levels in isolates 1 to 15 and is dramatically increased in isolates 16 and 17, suggesting that CDR1 contributes to resistance only at the end of this series (Fig. 5) . The background hybridization in lanes 16 and 17 was more intense because the Northern blot was first hybridized to CDR and then to ACT1. The intense signal for CDR in lanes 16 and 17 could not be completely removed before hybridization with the ACT1 probe. Therefore, the background hybridization was more intense. Phosphorimaging was used to analyze the amount of overexpression. The CDR band was quantitated based on the ACT1 band only. Quantitation suggests that CDR1 is increased approximately fivefold in isolates 16 and 17.
Recent work by several researchers has identified four other CDR genes that may be involved in drug resistance. Preliminary work shows that these genes cross-hybridize to each other under the conditions used (3, 38, 39, 45) . Therefore, the increased mRNA levels seen in isolates 16 and 17 can be attributed to one of the CDR genes, but which of the genes it should be attributed to cannot be determined by this analysis.
Constant mRNA levels of other ABC transporters. As discussed in the introduction, a gene from each of four families of the ABC transporters has been identified in C. albicans. The CDR genes described above are members of the PDR gene   FIG. 2 . Northern blots probed with ERG16. Total RNA (20 g) from each isolate was electrophoresed through a formaldehyde agarose gel, blotted onto nitrocellulose, and probed with labeled DNA from ERG16. The blots were washed and exposed to X-ray film. Subsequently, the blots were rehybridized with a labeled probe for ACT1. RNA from isolate 16 was accidentally run between isolates 9 and 11 but has been moved to its appropriate location in the figure.   FIG. 3 . Southern blots probed with ERG16. Genomic DNA (10 g) was digested with HincII, electrophoresed through an agarose gel, blotted onto nitrocellulose, and probed with labeled DNA from ERG16. The blots were washed and exposed to X-ray film. Slight variations in the intensity of each lane correspond with slight variations in the amount of DNA that was loaded in the gel (45).
FIG. 4. Northern blots probed with MDR1.
Total RNA (20 g) from each isolate was electrophoresed through a formaldehyde agarose gel, blotted onto nitrocellulose, and probed with labeled DNA from MDR1. The blots were washed and exposed to X-ray film. Subsequently, the blots were rehybridized with a labeled probe for ACT1.
family. To survey the other three families of ABC transporters, Northern blots of the entire series were hybridized with the gene probes listed in Table 1 . Since no changes were observed in the series, Fig. 6 shows only Northern blot analyses from the first two isolates (1 and 2) and the last two isolates (16 and 17) . For ELF1 and YCF1, Northern blots from these four isolates illustrate the constancy of mRNA levels in the series for each probe. No change in mRNA levels is detected throughout the series for either of these two ABC transporter genes, members of the YEF and CFTR gene families.
Northern blot analysis (45) was also performed on HST6, a member of the MDR gene family that appears to be the Candida homolog of the STE6 gene of Saccharomyces. No HST6 mRNA was detected in any of the isolates from this series. Control blots of genomic DNA indicate that the hybridizations were working correctly, and hybridization of the Northern filters with the ACT1 probe indicated that the filters were functional. This suggests that HST6 is not expressed at detectable levels in the isolates under these growth conditions. Constant mRNA levels of genes involved in ergosterol biosynthesis. The increased mRNA levels of ERG16 may be specific to the gene, or common to several genes in the ergosterol biosynthetic pathway. In addition to ERG16, two other genes in the same pathway, ERG1 and ERG7, have been cloned and sequenced. Probes to these genes were used against Northern blots of total RNA from the series (Fig. 6) . The mRNA levels of these genes are not altered in the series. Similarly, a probe for PRD1, the reductase associated with ERG16, was used against Northern blots of total RNA from the series (Fig. 6) ; mRNAs levels for PRD1 are not altered in the series. Relative decreases in band intensity observed for YCF1, ERG1, ERG7, and PDR1 are comparable to the relative decreases for ACT1. Phosphorimager analysis confirmed that the relative changes were proportional. In addition, Fig. 6 presents only 4 of the 17 isolates. In order to minimize the size of the figure, the entire series is not presented. Inspection of the entire series for each gene confirms the constant expression of the genes throughout the series (45) . This suggests that increased mRNA levels are restricted to ERG16 and are not a general characteristic of the ERG biosynthetic pathway or genes associated with the pathway.
DISCUSSION
The results presented above (summarized in Fig. 1 ) continue an analysis of the series of 17 isolates from a single AIDS patient. From this and previous analyses (29, 32, 44, 48) , it is clear that several genetic alterations are involved in the development of resistance in this series, including the selection of a substrain of C. albicans, isolate 2, demonstrated by a shift in Ca3 pattern (48) , increased mRNA levels of MDR1 (for isolate 1 compared to isolates 2 and 3 and beyond), genetic alterations in ERG16, including an Erg16 enzyme with increased resistance to fluconazole, a point mutation within ERG16 and a loss of allelic variation in the ERG16 region (44), increased mRNA levels of ERG16 (all occur between isolate 12 and 13), and increased mRNA levels of CDR (in isolates 16 and 17) .
The MICs in Fig. 1 suggest that changes in ERG16 and overexpression of CDR are associated with increased crossresistance to itraconazole and ketoconazole, consistent with previous observations (40) . These changes in MICs are associated with clinical breakpoints. For fluconazole, isolates 12 to 15 show intermediate levels of susceptibility (16 to 32 g/ml), while isolates 16 and 17 show resistant levels of susceptibility (Ն 64 g/ml) (33) . Similarly, MICs of itraconazole are inter- FIG. 5 . Northern blots probed with CDR1. Total RNA (20 g) from each isolate was electrophoresed through a formaldehyde agarose gel, blotted onto nitrocellulose, and probed with labeled DNA from CDR1. The blots were washed and exposed to X-ray film. Subsequently, the blots were rehybridized with a labeled probe for ACT1. The strong smearing in lanes 16 and 17 when the isolates were probed with ACT1 is due to the CDR1 signal that could not be removed before probing with ACT1.
FIG. 6.
Northern blots of total RNA from isolates 1, 2, 16, and 17 probed with ABC1 (renamed ELF1), YCF1, ERG1, ERG7, and PRD1. Total RNA (20 g) from each isolate in the series was electrophoresed through a formaldehyde agarose gel, blotted onto nitrocellulose, and probed with labeled DNAs as indicated. The blots were washed and exposed to X-ray film. Subsequently, the blots were reprobed with a labeled oligonucleotide for ACT1. Since no change is observed in the series for each probe, only the first two isolates and the last two isolates in the series are presented in the figure. mediate in resistance for isolates 13 to 15 (0.25 to 0.5 g/ml) and resistant for isolates 16 and 17 (Ն1 g/ml) (33) . MICs of ketoconazole are close to the resistant breakpoint for isolates 13 to 15 (0.06 to 0.12 g/ml) and highly resistant for isolates 16 and 17 (Ն0.25 g/ml) (35) . None of the changes shown in Fig.  1 appears to affect the level of amphotericin B susceptibility (Fig. 1) , which is consistently clinically sensitive (Ͻ1 g/mL). Since resistance in this series of isolates is an accumulation of several mechanisms, generalizations about specific mechanisms and clinical resistance to the azoles should not be drawn.
It is important to stress that changes in mRNA levels are not necessarily the result of an increase in transcription. Changes in mRNA levels can be the result of alterations in capping and polyadenylation, in mRNA transport from the nucleus, in translation rates of the mRNA, and in mRNA degradation, all of which can occur by several pathways. The results for this series, and for the other clinical isolates that have been described (41) , clearly indicate that increased mRNA levels are associated with resistance. Further analysis is needed to determine the process by which mRNA levels for ERG16, CDR, and MDR1 were altered in these isolates. It is also important to stress that increased mRNA levels do not necessarily lead to increases in protein levels or enzymatic activity. Further analysis of the Erg16 enzyme is currently in progress.
Changes in the transcript levels of ERG16 (Fig. 2 ) have been described previously for Candida, although those changes were not associated with resistance (41) . Increased expression of the 14DM gene in S. cerevisiae has been described previously (4, 6, 12, 14) . In each case, increases in mRNA levels were associated with small increases in resistance. The increases in mRNA levels in Candida are not the result of gene amplification, as determined by Southern blot analysis (Fig. 3) . Increased mRNA levels may be due to a loss of allelic variation in the ERG16 gene region (44) . This loss of variation was most likely the result of gene conversion or mitotic recombination. If the donor allele in the gene alteration encoded a stronger promoter, the alteration would result in increased mRNA levels as documented here.
Increased mRNA levels for CDR and for MDR1 have been previously described for other clinical isolates (41) . However, this is the first clinical isolate in which both genes are expressed simultaneously. In addition, a series of isolates was not previously available to define the timing of the increased levels or to correlate those levels with levels of resistance as has been done with this series of 17 isolates. For both MDR1 and CDR, stepwise increases are associated with increased resistance (Fig. 1) . For MDR1, the increase builds from no detectable mRNA in isolate 1 to high levels of mRNA in isolate 3. For CDR, a large increase in mRNA levels is detected in both isolates 16 and 17. In describing the CDR increases, we have been unable to determine which of the five CDR genes is responsible for the mRNA increase because of cross-hybridization of the probes (45) .
The CDR genes are all members of the PDR family of ABC transporters. mRNA levels were also examined for members of three other families, MDR, CFTR, and YEF. Transcripts are not detected for HST6, a member of the MDR family. Transcripts are detected for ELF1, a member of the YEF family and YCF1, a member of the CFTR family, although the mRNA levels are the same throughout the series (Fig. 6 ). This suggests that in this series, increased mRNA levels are restricted to the PDR family and are not a general phenomenon of all ABC transporters. These findings are consistent with those for the ABC transporter families in Saccharomyces, for which the PDR family is most frequently associated with drug resistance. Further conclusions await the identification of other ABC transporters. At this time, MDR1 is the only major facilitator that has been identified in Candida.
Increased levels of ERG16 mRNA may also be correlated with transcriptional regulation of the entire ergosterol biosynthetic pathway. To test this, mRNA levels in the series were monitored for two other genes from the pathway, ERG1 and ERG7, and for PRD1, the gene encoding the NADPH reductase associated with ERG16 (Fig. 6 ). The transcripts from these genes are not altered in the series, suggesting that the transcriptional control of ERG16 mRNAs is not a general effect on every gene in the ergosterol pathway. The PRD1 gene has previously been monitored for expression in resistant clinical isolates (41) for which no change in expression was identified.
The summary of results in Fig. 1 emphasizes that resistance develops gradually and that a highly resistant isolate can be the result of several different genetic alterations. The order of these changes as defined by this series of isolates is probably not important because there is no evidence to suggest that increased levels of MDR1 must precede changes in ERG16. However, it is noteworthy that under selective pressure from an antifungal agent, Candida cells can generate a resistant phenotype by using a variety of different genetic changes. As each genetic alteration occurs, cells with that mutation can overgrow the more susceptible cells in the population. Under continued selective pressure from an antifungal agent, several rounds of genetic alteration and overgrowth can occur, and the final result is a highly resistant strain containing a collection of mutations, each of which contributes to the phenotype. These results have serious clinical implications for the prevention and treatment of antifungal resistance, since several unrelated mechanisms can contribute to the resistant phenotype in a strain of Candida.
